- Biochemical hypogonadism, defined by low free testosterone (FT), is common in men who achieve sustained virologic response (SVR) after successful HCV treatment.
Why this matters
- With this persistence of hypogonadism after successful viral treatment, enhanced awareness and potential screening are needed for this growing population, say researchers.
- Investigators in this observational study evaluated the prevalence of low testosterone in men with chronic HCV infection (N=327; mean age, 57±7 years; HIV coinfection=150) and in a longitudinal subset of men with known pre- and posttreatment testosterone levels (n=85).
- Median follow-up: 36 months.
- Funding: NIH.
- Patients with active HCV at baseline had higher total testosterone (TT; P<.0001 and sex hormone-binding globulin p than patients who achieved svr but ft was the same between groups.>
- Low TT (
- TT and SHBG decreased significantly (P<.0001 after svr in the longitudinal cohort whereas ft remained unchanged.>
- Low FT persisted after SVR (pretreatment, 58%; post-SVR, 54%; P=.72).
- Study data represent biochemical rather than clinically diagnosed hypogonadism.